Thalomid

(thalidomide)

ApprovedSmall molecule

Thalidomide is used to treat multiple myeloma (a type of blood cancer) and a skin condition called erythema nodosum leprosum that can occur in leprosy patients. It works by helping the immune system fight cancer cells and reducing inflammation.[2] Thalomid is currently approved and in use across 127 indications[4].[1]

Thalomid is one of 2045 small molecule programs targeting Glioma. It is currently in Approved.

127

Indications

309

Total Trials

Active Trials

2,044

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

AIDSApproved

Childhood CancerActive, not recruiting

MalnutritionActive, not recruiting

Peritoneum CancerApproved

HIV InfectionActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Chronic PancreatitisActive, not recruiting

HypoalbuminemiaApproved

Non-Hodgkins LymphomaApproved

GliomaPhase 2

Active, not recruiting

AIDSApproved

Approved

Childhood CancerPhase 2

Active, not recruiting

MalnutritionApproved

Active, not recruiting

Peritoneum CancerApproved

Approved

HIV InfectionPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Chronic PancreatitisPhase 2

Active, not recruiting

HypoalbuminemiaApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Showing 10 of 124 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

2 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

Prolia

14 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Injury

NCT06617182

Phase 3Active, not recruiting

Multiple Myeloma

NCT00098475

Phase 3Recruiting

Nausea and Vomiting

NCT06017284

Phase 2Active, not recruiting

Trial

NCT00871013

Recruiting

Study completion

NCT06382519

Q1 2027

Phase 2Active, not recruiting

Myelofibrosis

NCT03069326

Clinical

Trials by Indication[1]

Multiple Myeloma45 trials

Thalidomide for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038233·27 enrolled

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00452569·499 enrolled

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Show 42 more trials

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn·TThe Cleveland Clinic·Phase 2·NCT00112879

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Unknown status·UUniversity Hospital, Bonn·Phase 2·NCT00124813·80 enrolled

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

Completed·UUniversity of Turin, Italy·Phase 2·NCT00358020·30 enrolled

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193544·40 enrolled

Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma

Unknown status·JJinling Hospital, China·Phase 3·NCT02248428·130 enrolled

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00319865·47 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00523848·46 enrolled

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status·PProf Jamie Cavenagh·Phase 1/2·NCT02145715·54 enrolled

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02559154·80 enrolled

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Terminated·EEmory University·Phase 2·NCT04352205·17 enrolled

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00657488·400 enrolled

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00538824·5 enrolled

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT01537861·7 enrolled

The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy

Unknown status·WWuhan University·Phase 1·NCT02467647·500 enrolled

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00033332

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Completed·MMario Boccadoro·Phase 2·NCT02586038·175 enrolled

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00049673·332 enrolled

Thalidomide-Dexamethasone for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00038090·83 enrolled

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00124579·7 enrolled

Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

Completed·UUniversity Hospital, Lille·Phase 3·NCT00367185·500 enrolled

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Unknown status·MMichele Cavo·Phase 3·NCT01134484·480 enrolled

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00098475·452 enrolled

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028886·450 enrolled

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·—·Phase 2·NCT00792142·45 enrolled

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00054158·24 enrolled

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Completed·UUniversità Politecnica delle Marche·Phase 3·NCT00633542·103 enrolled

Study of Combination PS-341 and Thalidomide in Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 1·NCT00083460·86 enrolled

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Completed·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT01341262·378 enrolled

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02891811·124 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00075829·710 enrolled

CURATE.AI Optimized Modulation for Multiple Myeloma

Unknown status·NNational University Hospital, Singapore·Phase 2/3·NCT03759093·20 enrolled

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Terminated·—·Phase 3·NCT00644306·232 enrolled

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00008242

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Completed·CCigdem Sahinbas YILMAZ·Phase 3·NCT00934154·122 enrolled

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 4·NCT00652041·40 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005834·19 enrolled

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00049374

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01632150·51 enrolled

Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients

Completed·SSilvio Aime·Phase 1/2·NCT00406978·24 enrolled

Prostate Cancer5 trials

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Completed·NNuvance Health·Phase 2·NCT00046826

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Completed·UUniversity of Pittsburgh·Phase 2·NCT00307294·40 enrolled

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00004635·159 enrolled

Show 2 more trials

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

Terminated·TThe Methodist Hospital Research Institute·Phase 2·NCT00450008·9 enrolled

A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001446·64 enrolled

Dexamethasone5 trials

High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP

Withdrawn·SShandong University·Phase 2·NCT01976195

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT00215943·90 enrolled

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Completed· Takeda logo

Takeda·Phase 3·NCT00507416·502 enrolled

Show 2 more trials

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Unknown status·LLi Zheng·Phase 1/2·NCT04891744·48 enrolled

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Completed·UUniversity of Arkansas·Phase 3·NCT00083915·97 enrolled

Kidney Cancer4 trials

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019539

Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer

Unknown status·CCancer Research UK·Phase 2·NCT00027664·90 enrolled

Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00005966

Show 1 more trial

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Terminated·MMedical University of South Carolina·Phase 2·NCT00090870·10 enrolled

Liver Cancer4 trials

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

Completed·—·Phase 2·NCT00058487·12 enrolled

Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00276705·47 enrolled

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006016·75 enrolled

Show 1 more trial

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006006·38 enrolled

98 more indications

Maintenance Therapy3 trials

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02844309·44 enrolled

Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

Completed·UUniversity of Miami·Phase 2·NCT02507336·2 enrolled

Mantle Cell Lymphoma3 trials

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00151281·25 enrolled

Malignant Glioma3 trials

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Terminated·RRush University Medical Center·Phase 2·NCT00014443·5 enrolled

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Completed·—·Phase 2·NCT00047281

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

Completed·WWake Forest University Health Sciences·Phase 2·NCT00079092·18 enrolled

Metastatic Melanoma3 trials

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00017316·35 enrolled

Biochemotherapy With Temozolomide for Metastatic Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505635·5 enrolled

Thalidomide and Dacarbazine for Metastatic Melanoma

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006200

Beta-Thalassemia3 trials

Long Term Beta Thalassemia Treatment: Findings From The Extension Period

Active, not recruiting·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06490601·30 enrolled

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Recruiting·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06490627·54 enrolled

Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients

Completed·BBlood Care Clinic·Phase 3·NCT06146478·200 enrolled

Non-Small Cell Lung Cancer3 trials

Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00025285·46 enrolled

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00281827·22 enrolled

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00004859·589 enrolled

Macroglobulinemia2 trials

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Completed·UUniversity of Arkansas·Phase 2·NCT00083707·40 enrolled

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00142116·25 enrolled

Myelodysplastic Syndromes2 trials

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00050843·220 enrolled

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Completed·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00455910·112 enrolled

Primary Systemic Amyloidosis2 trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Completed·SSWOG Cancer Research Network·Phase 2·NCT00064337·104 enrolled

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167

Glioblastoma Multiforme2 trials

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

Completed·—·Phase 2·NCT00039468·26 enrolled

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·—·Phase 2·NCT00047294

Lymphoma2 trials

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT02733380·20 enrolled

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Unknown status·HHuiqiang Huang·Phase 3·NCT02085655·264 enrolled

HIV wasting syndrome2 trials

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00002127·75 enrolled

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002157

Idiopathic Pulmonary Fibrosis2 trials

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Completed·JJohns Hopkins University·Phase 3·NCT00600028·25 enrolled

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

Completed·JJohns Hopkins University·Phase 2·NCT00162760·19 enrolled

Myelofibrosis2 trials

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Completed·MMayo Clinic·Phase 2·NCT00445900·22 enrolled

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03069326·30 enrolled

AL amyloidosis2 trials

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Unknown status·GGuangdong Provincial People's Hospital·Phase 4·NCT04612582·70 enrolled

A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis

Completed·UUniversity College, London·Phase 1/2·NCT02545907·10 enrolled

Myeloma2 trials

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Completed·GGruppo Italiano per lo Studio del Mieloma Multiplo·Phase 3·NCT00232934·400 enrolled

IFM 99-02 Thalidomide in Myeloma

Completed·UUniversity Hospital, Toulouse·Phase 3·NCT00222053·800 enrolled

Chronic Lymphocytic Leukemia2 trials

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00096018·43 enrolled

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·—·Phase 1·NCT00052416

Myelodysplastic Syndrome2 trials

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Completed·FFallon Clinic·Phase 2·NCT00053001

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00015990·29 enrolled

Nausea and vomiting2 trials

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

Completed·—·Phase 3·NCT02203253·642 enrolled

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Recruiting·FFudan University·Phase 3·NCT06017284·100 enrolled

Metastatic Colorectal Cancer2 trials

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05266820·120 enrolled

Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00019747·39 enrolled

Glioma2 trials

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00412542·78 enrolled

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00047879·7 enrolled

Waldenstrom macroglobulinemia2 trials

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01779167·4 enrolled

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00723658

Efficacy and Safety2 trials

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

Recruiting·—·Phase 2·NCT07187193·50 enrolled

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Completed·AAzienda Ospedaliera di Bolzano·Phase 2·NCT01526694·30 enrolled

Thalassemia2 trials

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

Completed·MMuhammad Aamir Latif·N/A·NCT06888232·121 enrolled

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Recruiting·—·Phase 4·NCT06299670·90 enrolled

Vascular Malformation2 trials

Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding

Withdrawn·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02754960

Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT00964496·55 enrolled

Venous malformation1 trial

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Completed·—·Phase 2·NCT00389935·14 enrolled

Hematologic Cancer1 trial

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00009984·70 enrolled

Exercise1 trial

Effects of Exercise in Combination With Epoetin Alfa

Completed·UUniversity of Arkansas·N/A·NCT00577096·120 enrolled

Leiomyosarcoma1 trial

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00033709

Amyloidosis1 trial

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

Unknown status·SSeoul National University Hospital·Phase 2·NCT02966522·30 enrolled

Chronic Prostatitis1 trial

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Terminated·KKenneth Peters, MD·Phase 2·NCT00301405·9 enrolled

Chronic Graft Versus Host Disease1 trial

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003894·36 enrolled

EGFR Mutation1 trial

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03341494·128 enrolled

Ovarian Reserve1 trial

Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT02998827·90 enrolled

Carcinosarcoma1 trial

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025506·55 enrolled

Metastatic Neuroendocrine Tumor1 trial

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027638

GastroIntestinal Bleeding1 trial

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

Withdrawn·TThe Cleveland Clinic·Phase 3·NCT00787436

Celecoxib1 trial

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Completed·—·Phase 2·NCT00165451·20 enrolled

Myeloproliferative Disorder1 trial

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Completed·—·Phase 2·NCT00274820·15 enrolled

CNS Tumors1 trial

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

Completed·UUniversity of New Mexico·Phase 1·NCT00251797·10 enrolled

Kaposi's sarcoma1 trial

Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019123

Sclerosing Cholangitis1 trial

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Terminated·MMayo Clinic·Phase 2·NCT00953615·1 enrolled

Thyroid Cancer1 trial

Thalidomide in Treating Patients With Thyroid Cancer

Completed·KKenneth Ain·Phase 2·NCT00026533

Metastatic Head and Neck Cancer1 trial

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003850·47 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

Gefitinib1 trial

Gefitinib Combined With Thalidomide to Treat NSCLC

Unknown status·BBai Jun·Phase 2/3·NCT02387086·380 enrolled

Leprosy1 trial

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

Not yet recruiting·MMedicines Development for Global Health·Phase 2·NCT07172659·45 enrolled

Ovarian Cancer1 trial

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016224

Injury1 trial

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Not yet recruiting·YYongquan Shi·Phase 2·NCT06617182·150 enrolled

Aphthous Ulcer1 trial

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000790·164 enrolled

Systemic Inflammatory Response Syndrome1 trial

The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

Terminated·—·Phase 3·NCT00529633·16 enrolled

Sarcoidosis1 trial

SARCOTHAL. Thalidomide in Skin Sarcoidosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305552·40 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

Plasma Cell Leukemia1 trial

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00258245·5 enrolled

Radiation Therapy1 trial

Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

Completed·WWake Forest University Health Sciences·Phase 2·NCT00049361

Cirrhosis1 trial

Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06772480·100 enrolled

NSCLC1 trial

Conmana Combined With Thalidomide to Treat NSCLC

Unknown status·HHenan Provincial People's Hospital·Phase 4·NCT02778893·67 enrolled

Unknown status·—·Phase 2·NCT01551641·180 enrolled

Sarcomas1 trial

Thalidomide in Treating Patients With Gynecologic Sarcomas

Completed·—·Phase 2·NCT00006005

Chronic Pancreatitis1 trial

Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis

Terminated·WWinthrop University Hospital·Phase 2·NCT00469703·10 enrolled

Neuroblastoma1 trial

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Completed·—·Phase 2·NCT00098865·15 enrolled

Refractory1 trial

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Completed·NNordic Myeloma Study Group·Phase 3·NCT00602511·300 enrolled

Mild to Moderate Alzheimer's Disease1 trial

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Unknown status·BBanner Health·Phase 2/3·NCT01094340·20 enrolled

Safety and Efficacy1 trial

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

Completed·—·Phase 1·NCT00002104

Dendritic Cell1 trial

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Completed·UUniversity of Arkansas·Phase 2·NCT00083538·40 enrolled

Soft Tissue Sarcoma1 trial

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00089544·23 enrolled

Malnutrition1 trial

Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients

Withdrawn·—·Phase 4·NCT00390247

Patients With Advanced Solid Tumors1 trial

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00062127·35 enrolled

Transplantation1 trial

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Terminated·UUniversity of Iowa·Phase 2·NCT01548573·19 enrolled

Resistance1 trial

Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance

Unknown status·VValme University Hospital·Phase 2·NCT00856804·10 enrolled

Hepatocellular Carcinoma1 trial

Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University·Phase 2/3·NCT00728078·200 enrolled

Angiogenesis1 trial

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed·UUniversity of Arkansas·Phase 2·NCT00083408·20 enrolled

Pneumonia1 trial

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT04273529·100 enrolled

Discoid Lupus Erythematosus1 trial

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001680·17 enrolled

Autoimmune Disease1 trial

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03122431·93 enrolled

Temozolomide1 trial

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00006358·44 enrolled

Systemic Mastocytosis1 trial

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed·—··NCT00769587

Systemic Sclerosis1 trial

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Terminated·NNYU Langone Health·Phase 1·NCT00418132·30 enrolled

Colorectal Cancer1 trial

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00310076·29 enrolled

Crohn's Disease1 trial

Thalidomide in Treating Crohn's Disease

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT02501291·47 enrolled

HIV infection1 trial

Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004276·50 enrolled

Ovarian Epithelial Cancer1 trial

Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

Completed·CCancer Research UK·Phase 2·NCT00004876·30 enrolled

Fallopian Tube Cancer1 trial

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00041080·139 enrolled

Medulloblastoma1 trial

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled

Adrenoleukodystrophy1 trial

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004450·60 enrolled

Endometrial Cancer1 trial

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025467·60 enrolled

Adenocarcinoma1 trial

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00083005·60 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT01485224·31 enrolled

Renal Cell Carcinoma1 trial

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Completed·SStanford University·Phase 2·NCT00226980·30 enrolled

Congestive Heart Failure1 trial

THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01640639·100 enrolled

Lenalidomide1 trial

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01125176·15 enrolled

Metastatic Prostate Cancer1 trial

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00020046

Diffuse Large B-Cell Lymphoma1 trial

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

Terminated·EEmory University·Phase 2·NCT00209014·2 enrolled

MPA1 trial

An Open Protocol for the Compassionate Use of Thalidomide

Completed·UUniversity of Arkansas·Phase 1/2·NCT00081757·250 enrolled

Unspecified9 trials

Thalidomide Therapy for VEOIBD

Recruiting·—··NCT06382519·40 enrolled

The Therapeutic Effect of Thalidomide in RI

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT03208413·58 enrolled

The Effective and Safety of Thalidomide in NTDT

Unknown status·XXiao-Lin Yin·Phase 2·NCT02995707·30 enrolled

Show 6 more trials

Use of Thalidomide in Patients With Arachnoiditis

Completed·WWashington University School of Medicine·Phase 2·NCT00284505·3 enrolled

Blood and Marrow Transplant Clinical Research Network

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00023530

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00572169·177 enrolled

The Effects of Thalidomide on Symptom Clusters

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00379353·32 enrolled

UARK 2003-33, Total Therapy III

Completed·UUniversity of Arkansas·Phase 2·NCT00081939·303 enrolled

The Effective and Safety of Thalidomide in TI

Unknown status·XXiao-Lin Yin·Phase 2·NCT03184844·100 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 16, 1998

THALOMID

NDA NDA020785

Sources

References

[1]
ClinicalTrials.gov — 309 trial records for thalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Thalomid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — thalidomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for thalidomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020785). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Thalomid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Multiple Myeloma45 trials

Prostate Cancer5 trials

Dexamethasone5 trials

Kidney Cancer4 trials

Liver Cancer4 trials

Maintenance Therapy3 trials

Mantle Cell Lymphoma3 trials

Malignant Glioma3 trials

Metastatic Melanoma3 trials

Beta-Thalassemia3 trials

Non-Small Cell Lung Cancer3 trials

Macroglobulinemia2 trials

Myelodysplastic Syndromes2 trials

Primary Systemic Amyloidosis2 trials

Glioblastoma Multiforme2 trials

Lymphoma2 trials

HIV wasting syndrome2 trials

Idiopathic Pulmonary Fibrosis2 trials

Myelofibrosis2 trials

AL amyloidosis2 trials

Myeloma2 trials

Chronic Lymphocytic Leukemia2 trials

Myelodysplastic Syndrome2 trials

Nausea and vomiting2 trials

Metastatic Colorectal Cancer2 trials

Glioma2 trials

Waldenstrom macroglobulinemia2 trials

Efficacy and Safety2 trials

Thalassemia2 trials

Vascular Malformation2 trials

Venous malformation1 trial

Hematologic Cancer1 trial

Exercise1 trial

Leiomyosarcoma1 trial

Amyloidosis1 trial

Chronic Prostatitis1 trial

Chronic Graft Versus Host Disease1 trial

EGFR Mutation1 trial

Ovarian Reserve1 trial

Carcinosarcoma1 trial

Metastatic Neuroendocrine Tumor1 trial

GastroIntestinal Bleeding1 trial

Celecoxib1 trial

Myeloproliferative Disorder1 trial

CNS Tumors1 trial

Kaposi's sarcoma1 trial

Sclerosing Cholangitis1 trial

Thyroid Cancer1 trial

Metastatic Head and Neck Cancer1 trial

Remission1 trial

Gefitinib1 trial

Leprosy1 trial

Ovarian Cancer1 trial

Injury1 trial

Aphthous Ulcer1 trial

Systemic Inflammatory Response Syndrome1 trial

Sarcoidosis1 trial

Trial1 trial

Plasma Cell Leukemia1 trial

Radiation Therapy1 trial

Cirrhosis1 trial

NSCLC1 trial

Hepatocellular Cancer1 trial

Melanoma1 trial

Oral1 trial

Esophageal Cancer1 trial

Sarcomas1 trial

Chronic Pancreatitis1 trial

Neuroblastoma1 trial

Refractory1 trial

Mild to Moderate Alzheimer's Disease1 trial

Safety and Efficacy1 trial

Dendritic Cell1 trial